Colazide balsalazide disodium data

SLX.S reported results of a Phase III U.K. trial that demonstrated better efficacy and safety of the balsalazide agent compared to mesalazine, a standard first-line treatment for ulcerative colitis. The median time to the first symptom-free day was 10 days, compared to 25 days for the existing treatment, as presented at the meeting of the British Society of Gastroenterology in Manchester.

The agent remains inactive until bacterial action in the colon splits it into the carrier molecule and the active agent, 5-ASA. Keeping the drug intact until it reaches the colon lessens the side effects associated with related drugs, such as nausea, headache, and male infertility. ...